Navigation Links
Serotonin the Answer for Anti-Obesity Treatment

According to a new research conducted at the University of Texas, Southwestern Medical Center it was found that increased serotonin aids to curb appetite.//

Serotonin is a brain chemical which can be stimulated by various drugs such Fen-phen and other diet drugs. That knowledge could aid in the design of safer anti-obesity drugs nearly a decade after Fen-phen was banned for causing harmful side effects. The study, which tested the effect of several drugs that alter serotonin levels in the brain, found that serotonin activates some neurons and melanocortin-4 receptors, or MC4Rs, to curb appetite and at the same time blocks other neurons that normally act to increase appetite.

The dual effect helps explain how such drugs, including Fen-phen, spur weight loss. The finding, available online and in the July 20 issue of Neuron, also reinforces the role of serotonin – a regulator of emotions, mood and sleep – in affecting the brain's melanocortin system, a key molecular pathway that controls body weight. "The more we understand about the pathways and the way serotonergic drugs regulate body weight, the more it one day might lead to harnessing beneficial properties of anti-obesity treatments like Fen-phen and minimizing the harmful side effects," said Dr. Joel Elmquist, professor of internal medicine at UT Southwestern and co-senior author of the study.

In the United States, about 66 percent of adults are obese or overweight, as are 16 percent of young people aged 6 to 19, according to the Centers for Disease Control and Prevention. The trend is significant because being overweight or obese increases the risk of harmful health consequences, such as heart disease, stroke, diabetes, non-alcoholic liver disease and death. Drugs that enhance the brain's release of serotonin have helped people lose weight. Fen-phen, which paired fenfluramine with phentermine, had such success. The drug combination, however, also led some patients to develop cardiac complications, Dr. Elmquist said.

The drug was removed from the market in 1997.But the mechanisms of how it caused weight loss were never fully determined, he said. So a few years ago, Dr. Elmquist and his research team set out to detail how fenfluramine affected the brain's molecular pathways to reduce appetite. In 2002, they examined the region of the brain's hypothalamus containing the arcuate nucleus, or ARC. In the ARC, drug-induced serotonin activates brain cells called pro-opiomelanocortin neurons, or POMC, which in turn release a hormone that acts on the MC4R to reduce appetite. The team's new study shows how serotonin also simultaneously blocks other neurons, known as NPY/AgRP, from being able to inhibit activity of MC4Rs. By blocking this inhibitory activity, serotonin prevents an increase in appetite.

Researchers studied the effect of Fen-phen and other serotonin-inciting drugs on both normal and genetically engineered lean and obese mice. They found that serotonin's dual regulation of POMC and AgRP neurons is necessary to promote weight loss. ‘The finding increases the understanding of the molecular circuitry that controls body weight in response to changing levels of serotonin,’ Dr. Elmquist said.

‘An overarching goal of this understanding, for humans, is to design specific, safe drugs to fight obesity.’ Dr. Elmquist, who recently left Harvard Medical School, directs the newly formed Center for Hypothalamic Research at UT Southwestern. The center, along with the Taskforce for Obesity Research, a National Institutes of Health Interdisciplinary Research Center, is part of the institution's effort to investigate the causes of obesity, metabolic syndrome and diabetes.

Source: Eurekaert
'"/>




Related medicine news :

1. Serotonin increases stroke risk
2. Disturbance in Serotonin Levels Result in Reduced Gasping In Kids with SIDS
3. Answer on SARS 3 to 4 weeks away
4. Answers For OCD soon
5. The Answer To Prevent Osteoporosis
6. Neurobiology Provides Answers To Block Memory-Related Drug Cravings
7. An Answer To Obesity: Weight Control Protein
8. Chronic Myelogenous Leukemia (CML) Has An Answer Now!
9. Synthetic Bone Tissue Could Be the Answer to Disfigurement Caused by Oral Cancer
10. Emotional Engagement of Husband - A Final Answer To What Women Want
11. US Preparing To Answer Japans Queries On Beef Exports
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... ... Quorum Health announced that Robert A. Vento has been appointed as president ... promoted to COO of QHR. , A national search was launched for ... in December 2016. , “I’m pleased to announce these leadership promotions ...
(Date:6/28/2017)... ... 2017 , ... Continually at the forefront of sweetener innovation, ... received the Non-GMO Project Verified seal. All five flavors of the plant-based, sugar-free ... verification for non-GMO foods and products in North America. , Available in Caramel, ...
(Date:6/28/2017)... , ... June 28, 2017 , ... Guide to FDA ... , No matter on which side of the Atlantic devicemakers do business, this ... they have to follow. , In addition to the full text of the FDA’s ...
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists on ... the flipper will get rich in no time. But what about the buyers of ... for the buyer of a flipped house. An email recently sent to Gary Case ...
(Date:6/28/2017)... ... June 28, 2017 , ... David B. Sosin, a founding partner at the ... the post of 2nd Vice President for the Illinois State Bar Association , in ... ISBA’s 3rd Vice President in 2016 following a state-wide election and served in that capacity ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a biotechnology ... Kineta Vice President of R&D and Head of ... Pandemic Preparedness for the Northwest and Beyond meeting ... on June 14, 2017 from 8:30-10:30 AM PDT at the ... Dr. Bedard will be joined by other ...
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
Breaking Medicine Technology: